Get all your news in one place.
100’s of premium titles.
One app.
Start reading

Tour de France sixth Quintana disqualified over tramadol use

Nairo Quintana won the last of his three Tour de France stages in 2019. ©AFP

Paris (AFP) - Colombian Nairo Quintana has been retrospectively disqualified from this year's Tour de France after testing positive for tramadol, the International Cycling Union (UCI) announced on Wednesday.

Former two-time runner-up Quintana, 32, finished sixth overall in the race which ended on July 24.

The pain medication has been banned by the UCI since 2019.

"The Union Cycliste Internationale (UCI) announces that the Colombian rider Nairo Alexander Quintana Rojas has been sanctioned for an infringement of the in-competition ban on using tramadol as set out in the UCI Medical Rules with the aim of protecting the safety and health of riders in light of the side-effects of this substance," the body said.

"The analyses of two dried blood samples provided by the rider on 8 and 13 July during the 2022 Tour de France revealed the presence of tramadol and its two main metabolites.

"In accordance with the UCI Medical Rules, the rider is disqualified from the 2022 Tour de France.This decision may be appealed before the Court of Arbitration for Sport (CAS) within the next 10 days.

"As this is a first offence, Nairo Alexander Quintana Rojas is not declared ineligible and can therefore participate in competitions," it added.

On Tuesday, Quintana's Arkea-Samsic team announced he had signed a contract extension until 2025 but he has been omitted from their squad for the Vuelta a Espana which begins on Friday.

Quintana won the Giro d'Italia in 2014 and the Vuelta two years later.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.